Journal
JOURNAL OF PROTEOME RESEARCH
Volume 6, Issue 11, Pages 4189-4199Publisher
AMER CHEMICAL SOC
DOI: 10.1021/pr070220c
Keywords
proteomics; 2-dimensional electrophoresis; DIGE cerebrospinal fluid; HIV; cognitive impairment; HAD
Categories
Funding
- NCRR NIH HHS [1P20RR11126, 20 RR15635, P20 RR011126] Funding Source: Medline
- NIMH NIH HHS [U01 MH083545, R21 MH075662, 1R21 MH075662-01] Funding Source: Medline
- NINDS NIH HHS [U54 NS043011, S11 NS046278, U54 NS4301, 1T32 NS07488] Funding Source: Medline
Ask authors/readers for more resources
Advanced HIV-1 infection is commonly associated with progressive immune suppression and the development of cognitive, motor, and behavior disturbances. In its most severe form, it is diagnosed as HIV-1 associated dementia (HAD) and can progress to profound functional disability and death. Despite prodigious efforts to uncover biomarkers of HAD, none can adequately reflect disease onset or progression. Thus, we developed a proteomics platform for HAD biomarker discovery and used it to perform a pilot study on cerebrospinal fluid (CSF) from HIV-1-infected people with or without HAD. A 2-dimensional electrophoresis (2-DE) map of a HAD CSF proteome was focused on differentially expressed proteins. 2-DE difference gel electrophoresis (2-D DIGE) analysis showed > 90 differences in protein spots of which 20 proteins were identified. Differential expression of 6 proteins was validated by Western blot tests and included vitamin D binding protein, clusterin, gelsolin, complement C3, procollagen C-endopeptidase enhancer 1, and cystatin C. We posit that these proteins, alone or together, are potential HAD biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available